$1,370,000 of TAKEDA PHARMACEUTICALS AMERICA INC lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"FY 2025 Budget Resolution - Pharmaceutical Related Provisions Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues Policies to enhance patient access to medicines in Medicare Review of proposed rule regarding testing of Medicare part B prescription drug models Discussions related to rebates and Medicare part D - provisions related to the HHS-OIG Rebate Safe Harbor Proposals related to amending the protected classes in Medicare Medicare payment proposals CMS Medicaid Drug Rebate Proposed Rule - issues related to best price and survey Request for Regulatory Clarification with Medicare Administrative Contractor (CMS) Discussions on spillover related to the IRA Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027 Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Discussions on reforming the Inflation Reduction Act Discussions on orphan drugs related to the IRA Discussions on treatment of small molecule drugs related to IRA H.R.1 492, S. 832, EPIC Act of 2025 H.R. 946, Optimizing Research Progress Hope and New (ORPHAN) Cures Act HR 4229 Protecting Patient Access to Cancer & Complex Therapies Act Clarify or reform the 340B program Value-based drug contracting Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Promoting the Congressional Plasma Caucus Pharmacy Benefit Managers (PBMs) Drug pricing, including House and Senate draft bills H.R. 2214, DRUG Act HP. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act Tax incentive issues as they relate to proposed global supply chain bills Discussions related to the repeal of the BEAT - provisions related to orphan drug tax credits Administration's Global Tax Proposal General issues around 2025 Reconciliation/Inbound Concerns Issues related to proposed Tariffs - all pharmaceutical related provisions Discussions around Supply Chain implications"
You can find more data on corporate lobbying on Quiver Quantitative.
TAK Hedge Fund Activity
We have seen 175 institutional investors add shares of TAK stock to their portfolio, and 103 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 2,842,012 shares (+1152.2%) to their portfolio in Q2 2025, for an estimated $43,937,505
- UBS GROUP AG added 2,270,084 shares (+129.4%) to their portfolio in Q2 2025, for an estimated $35,095,498
- MORGAN STANLEY added 1,917,066 shares (+33.6%) to their portfolio in Q2 2025, for an estimated $29,637,840
- BLACKROCK, INC. added 920,044 shares (+35.0%) to their portfolio in Q2 2025, for an estimated $14,223,880
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 899,298 shares (-26.2%) from their portfolio in Q2 2025, for an estimated $13,903,147
- VAN ECK ASSOCIATES CORP removed 840,952 shares (-38.7%) from their portfolio in Q2 2025, for an estimated $13,001,117
- GOLDMAN SACHS GROUP INC removed 819,828 shares (-15.4%) from their portfolio in Q2 2025, for an estimated $12,674,540
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
